ArticleBMC medicine2026
Genetic prioritization of HSDL2 in suicide and intentional self-harm: multi-omics evidence linking lipid metabolism and neuronal vulnerability.
Article in BMC medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundSuicide or other intentional self-harm (SSH) represents a critical global public health burden, yet biologically informed targets remain poorly defined due to its complex and incompletely understood etiology. This study aimed to prioritize genetically supported candidate targets for SSH and characterize their biological and translational relevance.
methodsWe developed a multi-omics evidence framework integrating transcriptomic and proteomic Mendelian randomization, colocalization, and sensitivity diagnostics. The primary SSH outcome was from FinnGen R12 (11,538 cases; 488,810 controls). eQTLGen and GTEx were used for transcriptomic analyses, and UKB-PPP and ARIC for proteomic validation. Downstream analyses included functional enrichment, tissue expression profiling, exploratory metabolomic pathway analysis, brain cell-type-specific eQTL analyses, phenome-wide liability scanning, structural modeling with docking, virtual screening and molecular dynamics simulations, and baseline SSH classification in UKB-PPP individual-level proteomic data.
resultsTranscriptome-wide MR identified 1,164 FDR-significant genes, of which 55 were retained as Tier 1-4 prioritized candidates after proteomic validation, colocalization, and sensitivity assessment. HSDL2 was the sole Tier 1 candidate, supported by consistent eQTL and pQTL evidence, adequate instrument strength, and colocalization at the HSDL2 locus (PP.H4 = 0.797). Genetically predicted HSDL2 expression was associated with higher SSH risk in eQTLGen (OR = 1.133, 95% CI: 1.076-1.192) and showed directionally consistent protein-level evidence in UKB-PPP (OR = 1.050, 95% CI: 1.005-1.098). Enrichment and metabolomic analyses implicated lipid-, bile acid-, and organelle-related pathways. Brain cell-type-specific analyses suggested neuronal involvement, with consistent excitatory-neuron associations across discovery and validation datasets and additional support for inhibitory neurons in SingleBrain, while oligodendrocyte signals required cautious interpretation. Structural analyses supported a putative HSDL2 ligand-binding pocket, providing hypothesis-generating structural context for the metabolic findings. Phenome-wide MR analyses identified additional disease associations, providing phenotypic context for future target evaluation. UKB-PPP baseline classification analyses provided complementary individual-level support for the prioritized protein signal.
conclusionsHSDL2 was prioritized as a genetically supported and biologically plausible candidate target for SSH, implicating a potential lipid-metabolic and neuronal vulnerability axis. These findings provide a foundation for future mechanistic validation and translational investigation.
Indexed as
Identifiers
42920133What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.